Press Releases April 24, 2026 08:20 AM

Huize Holding Limited Files 2025 Annual Report on Form 20-F

Huize Holding Limited Files 2025 Annual Report on Form 20-F with the SEC

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
HUIZ

Huize Holding Limited, a leading insurance technology platform in Asia, announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The report is accessible on the SEC and company websites, reflecting the firm's commitment to transparency and regulatory compliance.

Huize Holding Limited Files 2025 Annual Report on Form 20-F
HUIZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Huize filed its 2025 annual report (Form 20-F) with the SEC, affirming regulatory compliance as a U.S.-listed company.
  • The company leverages AI and data analytics to connect consumers, insurance carriers, and distribution partners in Asia's insurance sector.
  • Huize targets mass affluent consumers, providing an online-to-offline integrated insurance ecosystem covering the full insurance lifecycle.

SHENZHEN, China, April 24, 2026 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize,” the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers, and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026.

The annual report can be accessed on the SEC’s website at www.sec.gov and on the Company’s investor relations website at http://ir.huize.com. The Company will provide hardcopies of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to the Company’s Investor Relations Department at investor@huize.com.

About Huize Holding Limited

Huize Holding Limited is a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia. Targeting mass affluent consumers, Huize is dedicated to serving consumers for their life-long insurance needs. Its online-to-offline integrated insurance ecosystem covers the entire insurance life cycle and offers consumers a wide spectrum of insurance products, one-stop services, and a streamlined transaction experience across all scenarios. By leveraging AI, data analytics, and digital capabilities, Huize empowers the insurance service chain with proprietary technology-enabled solutions for insurance consultation, user engagement, marketing, risk management, and claims service.

For more information, please visit http://ir.huize.com or follow us on social media via LinkedIn (https://www.linkedin.com/company/huize-holding-limited), X (https://x.com/huizeholding), and Webull (https://www.webull.com/quote/nasdaq-huiz).

For investor and media inquiries, please contact:

Investor Relations
investor@huize.com

Media Relations
mediacenter@huize.com

Christensen Advisory
Dolly Zhang
Phone: +852 6996 4179
Email: dolly.zhang@christensencomms.com


Risks

  • Dependency on regulatory compliance in both U.S. and Chinese markets could impact operations if regulatory environments change.
  • Competition in the insurance technology space in Asia is intensifying, which may affect Huize's market share.
  • Technological risks related to AI and data analytics performance could impact service quality and customer satisfaction.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026